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Abstract
Background. Vitamin D played a role in the pathogenesis of systemic lupus erythematosus (SLE). Vitamin D 
made dendritic cells more tolerogenic to autoantigens and inhibited B cells from producing autoantibodies. 
Vitamin D deficiency would make dendritic cells intolerant, increased production of interferons, and B cells 
produce excessive autoantibodies. These excessive autoantibodies and interferons would have caused severe 
clinical manifestations in SLE patients
Aims. This study was to find out vitamin D deficiency would increase the proportion of severe clinical 
manifestations in SLE patients in the Dr. Sardjito General Hospital.  
Methods. We conducted a cross-sectional study. Data was taken from medical records of SLE patients who 
went to Dr. Sardjito General Hospital in 2018. The independent variable was serum 25(OH) D levels, 
which were divided into deficiency (≤12 ng/ml) and not deficiency (>12ng/ml). The dependent variable was 
the clinical manifestations of SLE patients, which were divided into mild-moderate and severe. Association 
between two variables was analyzed using Chi-Square.
Results. Vitamin D deficiency was observed in 19(54%) and not deficiency in 16(46%) subjects. SLE 
patients who underwent vitamin D deficiency more often experienced severe clinical manifestations than 
those without (52.6% versus 12.5%), prevalence ratio 4.2 CI 1.1-16.5 p=0.015. SLE patients who underwent 
vitamin D deficiency were more likely to suffer mucocutan, musculoskeletal, and kidney disorders. Also 
more likely to suffer more than 2 organ disorders than those without (57.9% versus 12.5%), prevalence 
ratio 4.6 CI 1.2-17.9 p=0.007.
Conclusions. Vitamin D deficiency increased the proportion of severe clinical manifestations in SLE patients 
at Dr. Sardjito General Hospital. It also increased the proportion of mucocutan disorder, musculoskeletal 
disorder, and kidney disorder. Also, it increased the proportion of occurrence of more than 2 organ disorders 
in SLE patients at Dr. Sardjito General Hospital.
Keywords: Vitamin D, SLE, clinical manifestations
Abstrak
Latar Belakang: Vitamin D berperan dalam patogenesis lupus eritematosus sistemik (LES). Vitamin D membuat 
sel dendritik lebih tolerogenik terhadap autoantigen dan menghambat sel B memproduksi autoantibodi. Defisiensi 
vitamin D akan membuat sel dendritik tidak tolerogenik, produksi interferon meningkat, dan sel B menghasilkan 
Acta Interna The Journal of Internal Medicine, Volume 10, Number 2, December 2020: 80-87
81 
Introduction
The role of vitamin D in the immune 
system was discovered in 1980.  Vitamin D 
receptors are found in the immune system 
such as dendritic cells, macrophages, and 
lymphocytes. These cells have the enzyme 
1α-hydroxylase and CYP27B1 which can 
convert vitamin 25(OH)D into its active 
form.1
Vitamin D acts as an immune modulator, 
especially in dendritic cells. Dendritic cells present 
antigens to T cells. Dendritic cells can maintain 
peripheral tolerance to autoantigens, thereby 
causing T cell anergy to autoantigens. Vitamin D 
deficiency can cause autoimmune disorders such 
as systemic lupus erythematosus (SLE).2
The cause of vitamin D deficiency in 
SLE patients can be exacerbated by the use of 
sunscreen, lupus nephritis, the habit of avoiding 
sunlight, long-term use of glucocorticoids, and 
the use of chloroquine.1
Clinical manifestations of SLE vary 
from mild-moderate to severe. Mild clinical 
manifestations are SLE with musculoskeletal 
and mucocutaneous disorders. Moderate 
clinical manifestations are found in one of 
the following signs, namely mild-moderate 
nephritis, platelets 20-50 x103/mm3, or 
serositis. Severe clinical manifestations are 
found in one of the following disorders, namely 
pericarditis, pneumonitis, severe nephritis, 
severe vasculitis, a diffuse rash with ulcers, 
neurology, and hematology (hemolytic anemia, 
neutropenia, and thrombocytopenia <20.000/
mm3).3
Miscovick et al (2015), found no 
relationship between vitamin D levels and 
clinical manifestations of SLE patients.1 
Different result was discovered by Dall’ara et 
al (2017), found that vitamin D deficiency 
would make severe clinical manifestations of 
SLE.4 These result still controversial, so we 
did this study. The purpose of this study was 
autoantibodi berlebihan. Autoantibodi dan interferon yang berlebihan ini akan menimbulkan manifestasi klinis 
pasien LES yang berat. 
Tujuan. Tujuan penelitian ini adalah untuk mengetahui apakah defisiensi vitamin D dapat meningkatkan 
proporsi terjadinya manifestasi klinis berat pada pasien LES di RSUP Dr Sardjito.
Metode. Penelitian ini merupakan penelitian potong lintang. Data diambil dari rekam medis pasien LES yang 
berobat di RSUP Dr Sardjito tahun 2018. Variabel bebas adalah kadar vitamin D (25(OH)D) serum, yang 
dibagi menjadi defisiensi (≤12 ng/ml) dan tidak defisiensi (>12ng/ml). Variabel tergantung adalah manifestasi 
klinis pasien LES, yang dibagi menjadi ringan-sedang dan berat. Hubungan antara kedua variabel dianalisis 
dengan Chi Square.
Hasil. Subyek yang mengalami defisiensi kadar vitamin D sebanyak 19 (54%) dan yang tidak defisiensi sebanyak 
16 (46%). Pasien LES dengan defisiensi vitamin D lebih sering mengalami manifestasi klinis berat dibandingkan 
dengan yang tidak defisiensi (52,6% dibanding 12,5%) dengan rasio prevalensi 4,2 CI 1,1-16,5 p=0,015. Pada 
pasien LES dengan defisiensi vitamin D lebih sering mengalami gangguan sistem mukokutan, muskuloskeletal, dan 
ginjal. Pasien LES dengan defisiensi vitamin D juga lebih sering mengalami gangguan multi organ dibandingkan 
dengan yang tidak defisiensi (57,9% dibanding 12,5%) dengan rasio prevalensi 4,6 CI 1,2-17,9 p=0,007.
Kesimpulan. Defisiensi vitamin D meningkatkan proporsi terjadinya manifestasi klinis yang berat pada pasien 
LES di RSUP Dr Sardjito. Defisiensi vitamin D juga meningkatkan proporsi terjadinya gangguan sistem 
mukokutan, muskuloskeletal, dan ginjal. Selain itu, defisiensi vitamin D juga meningkatkan terjadinya gangguan 
lebih dari 2 organ pada pasien LES di RSUP Dr Sardjito.
Kata Kunci :Vitamin D, lupus eritematosus sistemik, manifestasi klinis
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serositis. Severe manifestations if there was one 
of the following signs, namely hematological 
disorders (hemolytic anemia, neutropenia, 
platelets <20.000/mm3), proteinuria ≥3+, 
vasculitis, and neuropsychiatry.
After being approved by the Ethics 
Committee of the Faculty of Medicine, Public 
Health and Nursing Gadjah Mada University 
and obtained a research permit from the 
Director of Dr. Sardjito General Hospital 
Yogyakarta, we began collecting data from 
medical records.
The results were tested for normality by 
the Shapiro-Wilk test. The basic characteristics 
displayed descriptively included the percentage, 
median, or mean according to the results of 
the data normality. The association between 
vitamin D levels with clinical manifestations 
of SLE patients was analyzed by Chi-Square 
and accompanied by p-value and a prevalence 
ratio with a 95% CI.
Result
Subjects who met the inclusion and 
exclusion criteria were 35 subjects in total. 
The sociodemographic characteristics of the 
subjects were shown in table 1. The research 
subjects were 34 (97.1%) women and 1 (2.9%) 
men. SLE was known to be more frequent in 
women than men with a ratio of 8-15:1. The 
median age of subjects was 30 years with a 
range between 18 to 65 years old. Subjects 
who were diagnosed at less than 32 years were 
25 (71.4%) and those over 32 years were 10 
(28.6%). Most SLE diagnosed at the age of 
24-32 and 12-17 years. Older age at diagnosis 
usually has severe clinical manifestations.5 
Body mass index (BMI) varies from 16 to 29.7 
kg/m2, mean value 20.6 mg/kg2. There were 3 
(8.6%) subjects with excess BMI. SLE patients 
to determine whether vitamin D deficiency 
would increase the proportion of severe clinical 
manifestations in SLE patients at Dr. Sardjito 
General Hospital. Subanalysis was done to 
find out whether vitamin D deficiency would 
increase the proportion of organ system 
disorder that occurs, and also whether vitamin 
D deficiency would increase the proportion of 
more than 2 organs involved in SLE patients 
at Dr. Sardjito General Hospital.
Method
This research was a cross-sectional study 
conducted from July 2019 to February 2020. 
Data was taken from the medical record of 
LES patients seeking treatment at Dr. Sardjito 
General Hospital in 2018.
Inclusion was SLE patients who were 
diagnosed from ACR 1997 criteria, aged over 
18 years old, had data on vitamin D levels, 
complete blood count, creatinine, and urinalysis 
results within a maximum examination range 
of 1 month. Exclusion were pregnant women, 
cancer patients, tuberculosis, diabetes mellitus, 
osteoporosis, serum creatinine above 1.3 mg/
dL, obesity, urinary tract infections, using 
vitamin D supplements, anti-convulsants, 
anti-fungi, anti-chemotherapy, antiretroviral, 
isoniazid, and rifampicin in the last 3 months.
The independent variable was serum 
vitamin D (25(OH) D) levels, which are 
divided into deficiency (≤12 ng/ml) and 
not deficiency (> 12 ng/ml). The dependent 
variable was the clinical manifestations of SLE 
patients, which are divided into mild-moderate 
and severe manifestations. Mild-moderate 
clinical manifestations if there was one of the 
following criteria, namely mucocutaneous 
disorders, musculoskeletal, proteinuria <3+ 
with dipstick, platelets 20-50x103/ mm3, or 
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with excess BMI were at risk of experiencing 
more severe manifestations.6
Table 1. Sociodemographic characteristics of 
subjects
Characteristics Number (%) Mean Median
Age (year) 30 (18-65)
Sex  
     Man 1 (2.9%)






Body Mass Index (kg/m3) 21(±2.62)
     Underweight
     Normal







Characteristics of clinical manifestation 
based on vitamin 25(OH) D levels were shown 
in table 2. Ten patients (83.2%) with levels 
of 25(OH) D less than 12 ng/ml had severe 
clinical manifestations of SLE. Whereas 2 
(16.7%) patients with vitamin 25(OH) D 
levels greater than 12 ng/ml had severe clinical 
manifestations. Hematologic, musculoskeletal, 
mucocutaneous, and kidney disorders were 
more common in patients with vitamin D 
deficiency compared with those without 
deficiency. Subjects experiencing vasculitis, 
serositis, and neuropsychiatric disorders were 
very few. Vasculitis experienced by 2 subjects, 
serositis 1 subject, and neuropsychiatric 
disorder 1 subject.
Characteristics of laboratory results were 
shown in table 3. Subjects with vitamin D 
deficiency were 19 (54%) subjects with an 
average of vitamin D level 7.5 ± 2.4 ng/ml, 
while those that non-deficiency were 16 (46%) 
subjects with an average of 18.2 ± 6.5 ng/ml. 
The most frequent hematological disorders 
were anemia 20 (57.1%) and lymphopenia in 
12 (34.3%) subjects. This was following the 
other study, that anemia and lymphopenia 
were the most common hematologic disorder 
in SLE.7 Proteinuria was more common in SLE 
patients with vitamin D deficiency compared 
to those without deficiency (69.2% versus 
30.8%). 
This result was quite interesting because 
deficiency of vitamin D in SLE patients also 
occurred in equator areas such as Yogyakarta. 
Previous studies mentioned that the prevalence 
of vitamin D deficiency in SLE patients in 
China was 84.3%, Australia 27.7%, Hong 
Kong 27%, Canada 17.9%, United States 
20%, and Spain 15%.8 The prevalence of 
vitamin D deficiency in SLE patients in the 
Table 3. Characteristics of laboratory result 














Leucopenia 2 (100%) 0 (0%)
Trombocytopenia 1 (100%) 0 (0%)
Proteinuria 9 (69.2%) 4 (30.8%)
Creatinin (mg/dl)





Table 2. Characteristics of clinical manifestation 









     Mild-moderate
     Severe
System disorders







     Musculosceletal 14 (77.8%) 4 (22.2%)
     Mucocutan 12 (80%) 3 (20%)
     Kidney 10 (83.3%) 2 (16.7%)
     Vasculitis 2 (100 %) 0 (0%)
     Serositis 1 (100 %) 0 (0%)
     Neuropsychiatric 0 (0%) 1 (100%)
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equator and also four-season countries can 
be caused by dietary sources of vitamin D, 
clothing models, sunscreen, medications, or 
vitamin D antibodies in serum.9
Discussion
The association between vitamin D 
levels and clinical manifestations of SLE 
patients are shown in table 4. SLE patients 
with vitamin D deficiency experienced more 
severe clinical manifestations compared to 
those without (52.6% versus 12.5%), with 
a prevalence ratio of 4.2 CI 1.1-16.5 p-value 
= 0.015. These results were in line with the 
literature that vitamin D deficiency would 
cause dendritic cells to lose their tolerogenic 
properties to autoantigens, activation of T 
helper 1, increased autoantibody production 
by B lymphocyte, and excessive interferon 
production, which would cause severe clinical 
manifestations of SLE.1,2
Sub analysis was conducted of the 
association between vitamin D levels and 
mucocutaneous disorder in SLE patients 
shown in table 5. SLE patients with vitamin 
D deficiency more often experienced 
mucocutaneous disorder compared with those 
without deficiency (63.2% versus 18.8%), with 
a prevalence ratio of 3.4 CI 1.1 to 9.8 p-value 
= 0.010. SLE patients with mucocutaneous 
disorders would usually be educated to avoid 
sunlight and use sunscreen. This could cause 
a decrease in the formation of provitamin D3. 
So that the measurement of vitamin 25(OH) 
D was found to be much lower results.9
Association between vitamin D levels 
and musculoskeletal disorders in SLE patients 
was conducted in table 6. SLE patients with 
vitamin D deficiency more often experienced 
musculoskeletal disorders compared with 
those without deficiency (73.7% versus 
25%), with a prevalence ratio of 2.9 CI 1.2-
7.2 p-value = 0.005. Immunopathogenesis of 
musculoskeletal disorders in SLE was caused 
by increased production of type 1 interferon 
by plasmacytoid dendritic cells, monocytes, 
synovial cells, and fibroblasts. Vitamin D 
deficiency would increase interferon production 
and musculoskeletal disorders occur.10
Association between vitamin D levels 
with hematological disorders in SLE patients 
Table 4. Association between vitamin D level and clinical manifestations of SLE 
Clinical manifestation of SLE Prevalence ratio
(95%CI)  p valueSevere Mild-moderate
n % n %
Vitamin D level Deficiency 10 52.6 9 47.4 4.2
(1.1-16.5)
0.015
No deficiency 2 12.5 14 87.5
Total 12 34.3 23 65.7
Table 5. Association between vitamin D level and mucocutan disorder in SLE 
Mucocutan disorders Prevalence ratio
(95%CI) p valueYes No
n % n %
Vitamin D level Deficiency 12 63.2 7 36.8 3.4
(1.1-9.8)
0.010
No deficiency 3 18.8 13 81.3
Total 15 42.9 20 57.1
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shown in table 7. There was no difference in 
the proportion of hematological disorders 
between patients with vitamin D deficiency 
and no deficiency (63.2% versus 50%) with a 
ratio of a prevalence of 1.2 CI 0.7-2.3 p-value 
= 0.330. Anemia and thrombocytopenia in 
SLE were due to immunological and non-
immunological processes. Immunological causes 
such as hemolytic anemia and antithrombopoetin 
antibodies. Non-immunological causes iron 
deficiency, chronic inflammation, medications, 
spinal cord suppression, and chronic infections. 
The most common causes of anemia in SLE were 
chronic disease and iron deficiency. It might cause 
no association was found between vitamin D 
levels and hematological disorders in this study. 11
Association between vitamin D levels 
and kidney disorders in SLE patients shown in 
table 8. SLE patients with vitamin D deficiency 
more often experienced kidney disorders than 
those without deficiencies (52.6% versus 
12.5%), with a prevalence ratio of 4.2 CI 1.1 
to 16.5 p= 0.015. Vitamin D protected renal 
podocytes by reducing autophageal activity in 
SLE patients. Vitamin D deficiency increased 
podocyte autophagial activity and caused 
kidney damage.12
We conducted a subanalysis of the 
association between vitamin D levels and the 
number of organs affected in SLE (Table 9). 
SLE patients with vitamin D deficiency more 
often experienced more than 2 organs affected 
compared with those without (57.9% versus 
12.5%), with a prevalence ratio of 4.6 CI 1.2-
17.9  p = 0.007.
Multivariate logistic regression analysis 
was performed to find confounding in this 




n % n %
Vitamin D
level
Deficiency 14 73.7 5 26.3 2.9
(1.2-7.2)
0.005
No deficiency 4 25 12 75
Total 18 51.4 17 48.6




n % n %
Vitamin D level Deficiency 12 63.2 7 36.8 1.2
(0.7-2.3)
0.330
No deficiency 8 50 8 50
Total 20 57.1 15 42.9




n % n %
Vitamin D level Deficiency 10 52.6 9 47.4 4.2
(1.1-16.5)
0.015
No deficiency 2 12.5 14 87.5
Total 12 34.3 23 65.7
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study. Overweight body mass index (BMI) 
and age of diagnosed SLE over 32 years were 
confounding in this study. According to 
existing research, SLE patients with excess 
BMI or obesity are associated with poor sleep 
quality, more comorbidities, and more severe 
organ damage.6,13
These results are consistent with the 
research of Saulescu et al (2018), that in systemic 
lupus erythematosus patients with excess body 
mass index and / or obesity are associated with 
poor sleep quality and a lazy lifestyle that can 
cause various comorbidities in LES patients. 
Similar results from the study of Kang et al 
(2020), in LES patients with obesity will increase 
the incidence of lupus nephritis and more severe 
organ damage. This is due to the more comorbids 
found in LES patients with excessive BMI, 
such as hypertension, pulmonary hypertension, 
dyslipidemia, diabetes mellitus, and the risk of 
atherosclerosis.
Conclusion
Vitamin D deficiency increased the 
proportion of severe clinical manifestations in 
SLE patients at Dr. Sardjito General Hospital. 
The deficiency increased the proportion of 
mucocutan, musculoskeletal, and kidney 
disorders in SLE patients at Dr. Sardjito 
General Hospital. Vitamin D deficiency also 
increased the proportion of occurrence of more 
than 2 organ disorders in SLE patients at Dr. 
Sardjito General Hospital.
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